through on its rumored acquisition of Salix Pharmaceuticals ( SLXP +5.5% ) without a shareholder vote. He claims that its attempts at acquisitions are desperate actions to thwart Valeant's ( VRX +0.7% ) takeover bid. Post your comment!
Salix Pharmaceuticals (NASDAQ: SLXP ) is up 9% premarket on light volume. Allergan is rumored to be buying the firm in an all-cash transaction in an effort to fend off Valeant (NYSE: VRX ). Post your comment!
By Wall Street Breakfast : Economy Under Treasury Secretary Jack Lew’s crackdown on inversions , the Treasury Department announced new tax rules late yesterday to deter U.S. companies from moving their domicile to countries with lower tax rates. The tax changes make it harder for companies to ...
turning down an offer from Actavis (NYSE: ACT ). The paper adds an Allerga/Salix deal, meant to thwart Valeant's (NYSE: VRX ) hostile bid for Allergan, could be announced "late this week or next." A source says Actavis is still interested in buying
Conglomerates appeared on the scene, they claimed "synergies" and had skyrocketing "earnings" by doing hostile M&A. There are striking parallels to Valeant Pharmaceutical's (NYSE: VRX ) business model and the adoration of Complete Story »
By Don Dion : Foamix Pharmaceuticals Ltd. (Pending: FOMX ), a specialty pharmaceutical company seeking to develop treatments for skin conditions, plans to raise $65.0 million in its upcoming IPO. The Rehovot, Israel-based firm will offer 5.9 million shares at an expected price range of $10-$12 per
By Wall Street Breakfast : Economy Hedge funds are cutting their long positions on cable , as the gap between "yes" and "no" votes for Scottish independence narrows. According to French asset management group Lyxor, investors on average have cut their positions from 5% of their net assets at the ...
Allergan (NYSE: AGN ) has reached an agreement with Bill Ackman's Pershing Square and Valeant (NYSE: VRX ) to hold a special shareholder meeting on the originally planned date, Dec. 18. After lining up investors who own a combined
AGN +0.1% ) shares lined up in support of the special shareholders meeting to install board members who favor Valeant's ( VRX +0.1% ) takeover bid. The 35% figure is significant because it preempts Allergan's efforts to exclude Pershing's 9
2014] Valeant Pharmaceuticals (NYSE: VRX ) is a developer and marketer of a range ..... contact lenses. You may not have heard of VRX , but it owns Bausch & Lomb, the eye care ..... blockbuster drugs that might cure cancer, VRX has focused on dermatology (skin care such